These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 29205362)
1. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma. Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362 [TBL] [Abstract][Full Text] [Related]
2. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. Winder DM; Chattopadhyay A; Muralidhar B; Bauer J; English WR; Zhang X; Karagavriilidou K; Roberts I; Pett MR; Murphy G; Coleman N J Pathol; 2011 Nov; 225(3):448-62. PubMed ID: 21952923 [TBL] [Abstract][Full Text] [Related]
4. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M. Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Kucia-Tran JA; Tulkki V; Smith S; Scarpini CG; Hughes K; Araujo AM; Yan KY; Botthof J; Pérez-Gómez E; Quintanilla M; Cuschieri K; Caffarel MM; Coleman N Br J Cancer; 2016 Jul; 115(2):212-22. PubMed ID: 27351213 [TBL] [Abstract][Full Text] [Related]
6. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. Caffarel MM; Coleman N J Pathol; 2014 Mar; 232(4):386-90. PubMed ID: 24659184 [TBL] [Abstract][Full Text] [Related]
7. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation. Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087 [TBL] [Abstract][Full Text] [Related]
8. Virus and Host Events in Squamous Carcinogenesis. Coleman N Keio J Med; 2016; 65(4):78. PubMed ID: 28025425 [TBL] [Abstract][Full Text] [Related]
9. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass. Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849 [TBL] [Abstract][Full Text] [Related]
10. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. Ng G; Winder D; Muralidhar B; Gooding E; Roberts I; Pett M; Mukherjee G; Huang J; Coleman N J Pathol; 2007 Jul; 212(3):325-34. PubMed ID: 17516585 [TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma. Caffarel MM; Chattopadhyay A; Araujo AM; Bauer J; Scarpini CG; Coleman N J Pathol; 2013 Oct; 231(2):168-79. PubMed ID: 23765377 [TBL] [Abstract][Full Text] [Related]
12. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice. Adrian-Segarra JM; Sreenivasan K; Gajawada P; Lörchner H; Braun T; Pöling J J Biol Chem; 2018 Dec; 293(52):20181-20199. PubMed ID: 30373773 [TBL] [Abstract][Full Text] [Related]
13. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo. Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma. Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648 [TBL] [Abstract][Full Text] [Related]
15. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226 [TBL] [Abstract][Full Text] [Related]
16. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. Zhang X; Li J; Qin JJ; Cheng WL; Zhu X; Gong FH; She Z; Huang Z; Xia H; Li H J Lipid Res; 2017 May; 58(5):895-906. PubMed ID: 28258089 [TBL] [Abstract][Full Text] [Related]
17. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2. Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430 [TBL] [Abstract][Full Text] [Related]
18. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353 [TBL] [Abstract][Full Text] [Related]
19. Oncostatin M pathway plays a major role in the renal acute phase response. Luyckx VA; Cairo LV; Compston CA; Phan WL; Mueller TF Am J Physiol Renal Physiol; 2009 Apr; 296(4):F875-83. PubMed ID: 19158344 [TBL] [Abstract][Full Text] [Related]